Review anchor
Cytochrome b-245 heavy chain
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Cytochrome b-245 heavy chain
CHEMBL1287627
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cytochrome b-245 heavy chain as ChEMBL target CHEMBL1287627, mapped to UniProt P04839. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1287627
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04839
NADPH oxidase 2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Cytochrome b-245 heavy chain matters
Cytochrome b-245 heavy chain is reviewed as NADPH oxidase 2 (UniProt P04839); the current evidence base includes 1 approved drug, 144 compounds, and 50 assays, with lead potency reaching pChEMBL 7.5.
Protein context
NADPH oxidase 2
NADPH oxidase 2 Sequence length is 570 aa.
Review this target as Cytochrome b-245 heavy chain, mapped to UniProt P04839. ChEMBL maps the protein component as NADPH oxidase 2. Sequence length is 570 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P04839
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 144 compounds, and 50 assays for this target. The dominant activity type is IC50. CHEMBL3347550 is the current potency anchor at pChEMBL 7.5.
Use CHEMBL3347550 as the tractability anchor when discussing potency (pChEMBL 7.5).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 7.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Cytochrome b-245 heavy chain matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P04839, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
144
Total Compounds
50
Total Assays
1
Approved Drugs
IC50: 184.0, KI: 22.0, EC50: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3347550
|
7.5 | IC50 | — |
|
|
No preferred name
CHEMBL3347551
|
7.5 | IC50 | — |
|
|
No preferred name
CHEMBL3733336
|
7.5 | IC50 | — |
|
|
No preferred name
CHEMBL5413611
|
7.3 | Ki | — |
|
|
No preferred name
CHEMBL397686
|
7.0 | IC50 | — |
Source Header